★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Johnson & Johnson Faces Patent Hurdles in Drug Business, Potentially Setting the Tone for Pharma Peers Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…McAlinden Research PartnersApril 18, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Potential Pfizer-Seagen Tie Up Could Mark Largest Deal in Years, Continue to Propel Biopharma M&A Trend A potential acquisition of Seagen by Pfizer, likely in the neighborhood of $40.0 billion, would be the biggest biopharma deal…McAlinden Research PartnersFebruary 27, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcarePolitics & Policy Psychedelics Continue to Secure Legislative Backing Across the North American Continent Throughout the past month, legislators in nearly half a dozen US states have introduced bills focused on reforming laws that…McAlinden Research PartnersJanuary 30, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene Editing FDA Approvals for Genetic Medicines Speed Ahead Despite Recent Setbacks in Base Editing Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…McAlinden Research PartnersDecember 8, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Another Blockbuster Biopharma Acquisition on Deck, May Set the Stage for Breakout M&A Activity in 2023 Three pharma giants are in the running to purchase Horizon Therapeutics in what will likely be a larger deal than…McAlinden Research PartnersDecember 1, 2022
★ Daily Intelligence Briefings (DIBs)Politics & PolicyServices Germany Breaks Ground on Legalizing Cannabis for Recreational Use, Expanding European Market Germany will soon legalize the acquisition and purchase of up to 30 grams of cannabis for recreational purposes, following several…McAlinden Research PartnersOctober 27, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets CRISPR Tech Closes in on First FDA Approval, New Treatment Methods Continue to Emerge The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…McAlinden Research PartnersSeptember 29, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Biopharma Space Showing Signs of a Burgeoning Buying Spree M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…McAlinden Research PartnersAugust 9, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsPolitics & Policy COVID Vaccines Continue to Drive Significant Pharma Revenues as BA.5 Variant Cases on the Rise Pharma giants Pfizer and Moderna just secured multi-billion dollar deals to supply the US government with more than 170 million…McAlinden Research PartnersAugust 1, 2022
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarketsPolitics & Policy Battered Psychedelics Stocks Rebound on Wave of Scientific, Legislative Support Psychedelic medicine, focused on alternative mental health therapies that utilize drugs like LSD, MDMA and psilocybin, is becoming increasingly popular…McAlinden Research PartnersJuly 18, 2022